Resistance to PARPis was already proposed and demonstrated very early in the preclinical setting using a PARPi-resistant pancreatic cancer cell line with the intragenic deletion of c.6174delT of BRCA2 [73]. Here, BRCA2 is linked to pancreatic neoplasm.